| Patents for C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397) |
|---|
| 04/01/2004 | WO2004026861A1 Process for producing paroxetine hydrochloride hydrate |
| 04/01/2004 | WO2004026860A1 Methods of crystal precipitation |
| 04/01/2004 | WO2004026859A1 Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | WO2004026856A1 Tocopheryl ester |
| 04/01/2004 | WO2004026844A1 Methods and compositions of novel triazine compounds |
| 04/01/2004 | WO2004026843A1 Benzodiazepine derivatives and pharmaceutical compositions containing them |
| 04/01/2004 | WO2004026842A1 Novel uracil derivatives and medicinal use thereof |
| 04/01/2004 | WO2004026829A2 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors |
| 04/01/2004 | WO2004026828A1 Pyrrole derivatives as antimycobacterial compounds |
| 04/01/2004 | WO2004026822A2 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| 04/01/2004 | WO2004026307A1 Triazole derivatives as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | WO2004026306A2 Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | WO2004026305A1 Diaryl ethers as opioid receptor antagonist |
| 04/01/2004 | WO2004026264A2 Novel aromatic compounds possessing antifungal or antibacterial activity |
| 04/01/2004 | WO2003099284B1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
| 04/01/2004 | WO2003097633A8 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 04/01/2004 | WO2003076408A3 Indazole derivatives that are activators of soluble guanylate cyclase |
| 04/01/2004 | WO2003028652A3 Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| 04/01/2004 | WO2003008410A8 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 04/01/2004 | WO2002076402A3 Fatty amine drug conjugates |
| 04/01/2004 | US20040063974 Antidepressants; anxiolytic agents; antiinflammatory agents; analgesics; antiemetics |
| 04/01/2004 | US20040063959 Esters and amides as PLA2 inhibitors |
| 04/01/2004 | US20040063955 Antichoelsterol agents; cardiovascular disorders; antihistamines; multiple sclerosis; antihistamines |
| 04/01/2004 | US20040063936 Pyrimidine derivatives and process for preparing the same |
| 04/01/2004 | US20040063935 Aliphatic nitrogenous five-membered ring compounds |
| 04/01/2004 | US20040063929 Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same |
| 04/01/2004 | US20040063772 1-(4-fluoro-3-cyanophenyl)-3-trifluoromethyl-5-pyrazolecarboxylic acid, 1-(4-fluoro-3-cyanophenyl)-3-trifluoromethyl-5-(2-furyl)pyrazole, and imidazole |
| 04/01/2004 | US20040063771 Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors |
| 04/01/2004 | US20040063757 Urotensin-ll receptor antagonists |
| 04/01/2004 | US20040063756 Administering a therapeutically effective amount of 2-Aminoquinolines for the prevention or treatment of eating disorders, weight gain and obesity |
| 04/01/2004 | US20040063755 Aromatic compounds containing hydroxyalkylaminoalkylphenylaminophenyl group; useful for treating pre-term labor, neurological disorders and cardiac disorders |
| 04/01/2004 | US20040063736 Combination of active ingredients containing alfuzosine and apomorphine |
| 04/01/2004 | US20040063735 Calcitonin gene related peptide receptor antagonists |
| 04/01/2004 | US20040063709 Acute and chronic inflammatory disorders; cancer |
| 04/01/2004 | US20040063705 Substituted pyrimidinyl derivatives and methods of use |
| 04/01/2004 | US20040063698 Inflammatory disorders; such as N-hydroxy-2-(2-(4-(2-methyl-quinolin-4-ylmethoxy)-phenyl)-tetrahydro-furan-2-yl)-acet-amide |
| 04/01/2004 | US20040063693 5-HT2A receptor related disorders; such as 1-(2-(2-fluoro-4-nitrophenoxy)ethyl)-3-(1piperazinyl)-2(1H)-pyrazinone |
| 04/01/2004 | US20040063691 Preparation and use of imidazole derivatives for treatment of obesity |
| 04/01/2004 | US20040063684 Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
| 04/01/2004 | US20040063671 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 04/01/2004 | US20040063665 Anticancer agents; high degree of discrimination toward malignant cells; reducing side effects; nontoxic; such as 3-chloro-2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4H-chromen-4-one |
| 04/01/2004 | US20040063645 Such as ((2-(3-guanidino-2-hydroxy-propylcarbamoyl)-1H-indol-5-yl)-amide) |
| 04/01/2004 | US20040063643 Bombesin antagonists |
| 04/01/2004 | US20040060568 Hedgehog antagonists, methods and uses related thereto |
| 04/01/2004 | CA2768674A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| 04/01/2004 | CA2499964A1 Methods and compositions of novel triazine compounds |
| 04/01/2004 | CA2499701A1 Pyrrole derivatives as antimycobacterial compounds |
| 04/01/2004 | CA2498781A1 Indolinones substituted by heterocycles, their preparation thereof and their use as medicaments |
| 04/01/2004 | CA2497971A1 Triazole derivatives as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | CA2496727A1 Process for producing paroxetine hydrochloride hydrate |
| 04/01/2004 | CA2496726A1 Methods of crystal precipitation |
| 03/31/2004 | EP1403269A1 Remedial agent for viral infectious disease |
| 03/31/2004 | EP1403268A1 Fluorescent probes for zinc |
| 03/31/2004 | EP1403267A1 Process for preparing glycidylphthalimide |
| 03/31/2004 | EP1403255A1 Rho KINASE INHIBITORS |
| 03/31/2004 | EP1403251A1 Bis(2-aryl-5-pyridyl) derivative |
| 03/31/2004 | EP1403250A1 Bis(5-aryl-2-pyridyl) derivative |
| 03/31/2004 | EP1402024A2 Templated molecules and methods for using such molecules |
| 03/31/2004 | EP1401962A1 Method for increasing hydrophilicity of fluorescent label compounds |
| 03/31/2004 | EP1401850A1 Nucleoside derivatives for library preparation |
| 03/31/2004 | EP1401832A1 High molecular weight hydroxyphenylbenzotriazole uv-absorbers for thin film applications |
| 03/31/2004 | EP1401828A1 N-formyl hydroxylamine compounds as inhibitors of pdf |
| 03/31/2004 | EP1401827A2 Herbicidal substituted pyridines, method for producing the same and their use as herbicidal agents and plant growth regulators |
| 03/31/2004 | EP1401826A1 Pyrazole derivatives as hiv reverse transcriptase inhibitors |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401820A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401819A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401575A1 Hydroxylation of beta-dicarbonyls with zirconium catalysts |
| 03/31/2004 | EP1401453A2 Protease inhibitors |
| 03/31/2004 | EP1401451A2 Quinazoline derivatives which promote the release of parathyroid hormone |
| 03/31/2004 | EP1401439A1 Use of bicyclo compounds for treating alzheimer's disease |
| 03/31/2004 | EP1401434A1 Modulators of peroxisome proliferator activated receptors (ppar) |
| 03/31/2004 | EP1401427A2 Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them |
| 03/31/2004 | EP1401351A2 Method for treating glaucoma vi |
| 03/31/2004 | EP1370258A4 Peptide deformylase inhibitors |
| 03/31/2004 | EP1021439B1 Crystalline antifungal polymorph |
| 03/31/2004 | EP0901470B1 Indole derivatives useful as endothelin receptor antagonists |
| 03/31/2004 | EP0788358B1 Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis |
| 03/31/2004 | CN1486312A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486311A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486310A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486309A Tetrahydroazepine derivatives useful as dopamine d3 receptor modulators (antipsychotic agents) |
| 03/31/2004 | CN1486302A Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 03/31/2004 | CN1143857C Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors |
| 03/31/2004 | CN1143856C Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) [1,4] diazepan-1-yl)-1-(aryl) butyl) benzamides useful for treatment of allergic diseases |
| 03/31/2004 | CN1143854C Novel 2-(iminomethyl) amino-phenyl derivatives,the preparation thereof, application as medicines and pharmaceutical compositions containing same |
| 03/31/2004 | CN1143853C Preparing method for anti-viral compounds |
| 03/31/2004 | CN1143849C Pyridine ketones used as herbicides |
| 03/31/2004 | CN1143848C 2-arylethyl-(piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists |
| 03/31/2004 | CN1143679C Method and material for treating and preventing mucosal tissue inflammation |
| 03/31/2004 | CN1143675C Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics |
| 03/30/2004 | US6713650 ABCA-1 elevating compounds |
| 03/30/2004 | US6713635 As chemical intermediates used for the preparation of s-alpha-ethyl-2-oxo-1-pyrrolidine acetamide |
| 03/30/2004 | US6713629 5,5-Disubstituted thiazolidine derivative pesticides |
| 03/30/2004 | US6713626 Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
| 03/30/2004 | US6713502 Anti-infectives |
| 03/30/2004 | US6713498 Method for treating glaucoma VI |
| 03/30/2004 | US6713489 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or syndrome x |
| 03/30/2004 | US6713487 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition |
| 03/30/2004 | US6713485 Antiproliferative agents; side effect reduction |